2009, Volume 16, Supplement 1

Pulmonary arterial hypertension (PAH) is a comparatively rare, chronic, progressive disease of unknown aetiology, which is characterised by increased pulmonary vascular resistance and which may...

Reviewing this topic, Professor Lewis J Rubin, University of California, San Diego, US, looked at both the successes and failures of the past 20 years....

Current data show that PAH patients are now older than previously reported, and more patients are identified with associated co-morbidities, according to Professor Marius Hoeper,...

Professor Nazzareno Galiè, University of Bologna, Italy, outlined the pathophysiological mechanisms of pulmonary arterial hypertension (PAH). These are initiated by the progressive obstructive changes of...

Professor Jean-Luc Vachiéry, Université Libre de Bruxelles, Belgium, began by looking at progress in the management of PAH over the last 50 years. Current therapies...